Zhu (2020)
Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019
https://doi.org/10.1016/j.ijid.2020.04.041
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195003/
Laboratory Findings
IL-6 (1 unit increase vs. Not applicable)
COVID-19 (severe/critical)
Odds ratio: 1.090 (1.040-1.147) Adjusted model

China

Retrospective cohort study

Medical records

127

127 consecutive hospitalized patients with confirmed COVID-19 at Hwa Mei Hospital, University of Chinese Academy of Sciences during January 23 to February 20, 2020 were enrolled into this retrospective study.

82 (64.57%) were woman and 45 (35.43%) were man, the mean age was 50.90 years. All patients were diagnosed according to the guidelines for diagnosis and treatment for COVID-19, and classified into mild, moderate, severe and critical type based on the severity of symptoms. 1) Severe patients should meet at least one of the following criterions: First, shortness of breath with respiration rate (RR)>=30 times/min. Second, oxygen saturation<=93% in resting state. Third, partial pressure of arterial oxygen (PaO2)-to-fraction of inspired oxygen (FiO2) ratio<=300 mm Hg. Obvious lesion progression >50% within 24-48 hours on pulmonary imaging were also recognized as severe cases. 2) Critical cases were defined when one of the following conditions met: First, respiratory failure and require mechanical ventilation. Second, shock occurred. Third, combined with other organ failure and treated in intensive care unit. 3) Mild and moderate cases were defined as non-severe group, while severe and critical patients were categorized as severe group in this study.

Total

4 Week


COVID-19 (severe/critical)

16

According to severity of the disease, 16 cases (12.60%) were categorized as severe group. 1) shortness of breath with respiration rate (RR)>=30 times/min. 2) oxygen saturation<=93% in resting state. 3) partial pressure of arterial oxygen (PaO2)-to-fraction of inspired oxygen (FiO2) ratio<=300 mm Hg. Obvious lesion progression >50% within 24-48 hours on pulmonary imaging were also recognized as severe cases.


Laboratory Findings

IL-6

Interleukin-6 (pg/ml)

Not applicable

1 unit increase


Odds ratio

1.090 (1.040-1.147)

No

Yes

Yes

Hypertension, C-reactive protein, Interleukin-6


IL-6 blockade treatment maybe a novel therapeutic strategy for treating the severe patients.

Average

Yes